Factors Affecting the Clinical Development of Cytochrome P450 3A Substrates

被引：0
|
作者：
Megan A. Gibbs
Natilie A. Hosea
机构：
[1] Pfizer Inc.,Clinical Pharmacokinetics and Pharmacodynamics
[2] Pfizer Inc.,Pharmacokinetics, Dynamics and Metabolism
来源：
Clinical Pharmacokinetics | 2003年 / 42卷
关键词：
Midazolam; Ketoconazole; Felodipine; Terfenadine; Grapefruit Juice;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The objective of this review is to evaluate the risks associated with the discovery and development of cytochrome P450 (CYP) 3A substrates.
引用
收藏
页码：969 / 984
页数：15
相关论文
共 50 条
  • [21] Cytochrome P450 3A polymorphisms and immunosuppressive drugs:: an update
    Anglicheau, Dany
    Legendre, Christophe
    Beaune, Philippe
    Thervet, Eric
    PHARMACOGENOMICS, 2007, 8 (07) : 835 - 849
  • [22] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    Flockhart, DA
    Rae, JM
    PHARMACOGENOMICS JOURNAL, 2003, 3 (01): : 3 - 5
  • [23] EFFECT OF CANNABIDIOL (CBD) ON CYTOCHROME P450 3A IN THE MOUSE
    BORNHEIM, LM
    EVERHART, ET
    LI, J
    FASEB JOURNAL, 1993, 7 (03): : A265 - A265
  • [24] Estrogen regulation of the cytochrome P450 3A subfamily in humans
    Williams, ET
    Leyk, M
    Wrighton, SA
    Davies, PJA
    Loose, DS
    Shipley, GL
    Strobel, HW
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (02): : 728 - 735
  • [25] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    D A Flockhart
    J M Rae
    The Pharmacogenomics Journal, 2003, 3 : 3 - 5
  • [26] How important is intestinal cytochrome P450 3A metabolism?
    van Herwaarden, Antonius E.
    van Waterschoot, Robert A. B.
    Schinkel, Alfred H.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (05) : 223 - 227
  • [27] Cytochrome P450 3A: Genetic polymorphisms and interethnic differences
    Krishna, DR
    Shekar, MS
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2005, 27 (08): : 559 - 567
  • [28] Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates
    Fujino, Chieri
    Sanoh, Seigo
    Katsura, Toshiya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (11) : 1617 - 1634
  • [29] Cytochrome P450 recognition sites for NADPH cytochrome P450 reductase and substrates.
    Dai, R
    Robinson, RC
    Friedman, FK
    BIOPHYSICAL JOURNAL, 1997, 72 (02) : MP290 - MP290
  • [30] Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions
    Wilkinson, GR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 99 - 103
12345